Treatment choice in EGFR-mutant non-small-cell lung cancer
Mené sur 452 patients atteints d'un cancer du poumon non à petites cellules EGFR+, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du dacomitinib et du géfitinib en traitement de première ligne
Palliative therapy for patients with non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation has improved with the approval of targeted therapy, namely the first-generation tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, which have both shown significant efficacy in terms of tumour response and progression-free survival when compared with platinum-based chemotherapy in phase 3 trials. The same is true for afatinib, which is a second-generation irreversible inhibitor of tyrosine kinase activity, of not only EGFR, but also all members of the HER (or ErbB) family (a pan-HER inhibitor).
The Lancet Oncology , commentaire, 2016